Enhertu demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumours
AstraZeneca and Daiichi Sankyo’s Enhertu showed an objective response rate of 37.1% in the overall population of the DESTINY-PanTumor02 Phase II trial. Enhertu is the first therapy to show broad activity across HER2-expressing advanced solid tumours where there are currently no approved HER2-directed therapies. DESTINY-CRC02 Phase II trial also demonstrated positive antitumour activity and consistent safety in patients with previously treated HER2-positive metastatic colorectal cancer.Positive results from an interim analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that